Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Hutchison MediPharma Ltd.

Division of Hutchison China MediTech Ltd.
www.hmplglobal.com

Latest From Hutchison MediPharma Ltd.

Divest, Refocus, Transition: Multinationals Embark On Uncharted Path In China

Facing unprecedented pricing pressures in China, multinationals are embarking on a major shift away from mature products to focus more on innovative drugs, but there are major challenges linked to the transition that won’t be easy to navigate, notes a new report.

China Business Strategies

Choose Carefully For China Drug Development Success: White Paper

By avoiding crowded space and focusing instead on therapeutic areas with large potential, China remains attractive for drug developers, notes a recent white paper from investment bank China E-Capital.

China Commercial

Cancer, Rare Disease Drugs To Be Covered As China Expands Reimbursement

China's national reimbursement drug list will undergo a much anticipated expansion in 2019, and therapies for cancer, pediatric and rare conditions from international firms including Roche and Actellion are likely to receive long-awaited coverage.

China Market Access

Oncology Dominates As China Approves Record 48 New Drugs In 2018

Despite multiple adverse factors including a leadership shakeup and the departure of its top regulator, the China FDA seemed determined to refresh itself after a name change and to speed up new drugs to market.

China Pink Sheet Perspectives
See All

Company Information

  • Industry
  • Biotechnology
    • Drug Discovery Tools
      • Molecular Diversity
        • Natural Products
  • Pharmaceuticals
  • Therapeutic Areas
  • Cancer
  • Immune Disorders
  • Alias(es)
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • Asia
      • China
  • Parent & Subsidiaries
  • Hutchison China MediTech Ltd.
  • Senior Management
  • Christian Hogg, Interim CEO
    Weiguo Su, PhD, EVP, Drug Research
    Mark Lee, VP, Corp. Fin. & Dev.
    May Wang, SVP, Bus. Dev. & Strategic Alliances
  • Contact Info
  • Hutchison MediPharma Ltd.
    Phone: (86) 20 5079 0088
    Bldg. 4, 720 Cai Lun Rd.
    ZJ Hi-Tech Park
    Shanghai, 201203
    China
Advertisement
Advertisement
UsernamePublicRestriction

Register